OBJECTIVES: To assess adherence to hydroxyurea therapy in children with sickle cell anemia (SCA), evaluate the association between adherence and hematologic profile, and identify barriers and facilitators of adherence. STUDY DESIGN: Children with SCA (n=75) receiving hydroxyurea were recruited for a single-institution cross-sectional study. The primary outcome was association between treatment adherence and percent fetal hemoglobin (HbF). RESULTS: Good adherence was estimated at 82% with visual analog scale, 84% with Morisky score, 85% with medical provider report, 77% with clinic visits, and 49% on the basis of pharmacy refills. Increase in HbF was moderately associated with good adherence as measured with the parent/proxy Morisky score (r=-0.39; 95% CI, -0.58-0.17; P < .01) and prescription refills (r=0.39; 95% CI, 0.16-0.57; P < .01). The number of pharmacy refills and the Morisky score explained 23% of the variation in HbF response. CONCLUSIONS: Adherence was > or =75% with 4 of 5 measures. Pharmacy refills and the Modified Morisky Scale may be used to identify children at high risk for poor response because of non-adherence and children with good adherence with poor response because of individual pharmacodynamics. Future research should prospectively compare adherence measures and evaluate methods to improve treatment adherence. Copyright 2010 Mosby, Inc. All rights reserved.
OBJECTIVES: To assess adherence to hydroxyurea therapy in children with sickle cellanemia (SCA), evaluate the association between adherence and hematologic profile, and identify barriers and facilitators of adherence. STUDY DESIGN:Children with SCA (n=75) receiving hydroxyurea were recruited for a single-institution cross-sectional study. The primary outcome was association between treatment adherence and percent fetal hemoglobin (HbF). RESULTS: Good adherence was estimated at 82% with visual analog scale, 84% with Morisky score, 85% with medical provider report, 77% with clinic visits, and 49% on the basis of pharmacy refills. Increase in HbF was moderately associated with good adherence as measured with the parent/proxy Morisky score (r=-0.39; 95% CI, -0.58-0.17; P < .01) and prescription refills (r=0.39; 95% CI, 0.16-0.57; P < .01). The number of pharmacy refills and the Morisky score explained 23% of the variation in HbF response. CONCLUSIONS: Adherence was > or =75% with 4 of 5 measures. Pharmacy refills and the Modified Morisky Scale may be used to identify children at high risk for poor response because of non-adherence and children with good adherence with poor response because of individual pharmacodynamics. Future research should prospectively compare adherence measures and evaluate methods to improve treatment adherence. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang Journal: Blood Date: 2005-10-01 Impact factor: 22.113
Authors: T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware Journal: Blood Date: 1999-09-01 Impact factor: 22.113
Authors: Matthew M Heeney; Matthew R Whorton; Thad A Howard; Christina A Johnson; Russell E Ware Journal: J Pediatr Hematol Oncol Date: 2004-03 Impact factor: 1.289
Authors: Courtney D Thornburg; Natalia Dixon; Shelly Burgett; Nicole A Mortier; William H Schultz; Sherri A Zimmerman; Melanie Bonner; Kristina K Hardy; Agustin Calatroni; Russell E Ware Journal: Pediatr Blood Cancer Date: 2009-05 Impact factor: 3.167
Authors: ElShadey Bekele; Courtney D Thornburg; Amanda M Brandow; Mukta Sharma; Arlene M Smaldone; Zhezhen Jin; Nancy S Green Journal: Pediatr Blood Cancer Date: 2014-04-17 Impact factor: 3.167
Authors: Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun Journal: Am J Hematol Date: 2017-06-15 Impact factor: 10.047
Authors: David G Bundy; John Muschelli; Gwendolyn D Clemens; John J Strouse; Richard E Thompson; James F Casella; Marlene R Miller Journal: J Pediatr Hematol Oncol Date: 2016-05 Impact factor: 1.289